RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
肿瘤细胞治疗研究
英文原题:Non-viral targeted integration at the CISH locus enables CAR-NK cell engineering with enhanced anti-tumor activity.
Non-viral targeted integration at the CISH locus enables CAR-NK cell engineering with enhanced anti-tumor activity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
自然杀伤(NK)细胞因其固有的细胞毒性而在过继性细胞治疗中具有前景。早期临床试验证实了其在癌症和自身免疫性疾病治疗中的安全性和有效性。用嵌合抗原受体(CAR)改造 NK 细胞可增强靶向特异性,并促进其作为现货型异体疗法的发展。
然而,NK 细胞的病毒载体和非病毒载体改造方法均面临挑战。在此,我们介绍 CISH 位点整合 CAR 杀伤细胞(CLICK),一种使用微型环状单链 DNA 基因组编辑系统的新型非病毒方法。CLICK 能够高效地将 CD19CAR 序列整合至代谢检查点 CISH 位点,同时破坏 CISH 并驱动外周血来源 NK 细胞中稳定且逐步增加的 CAR 表达。经 CLICK 改造的 CAR-NK 细胞表现出强效的细胞毒性、增强的体外和体内抗肿瘤活性、延长的持久性以及减少的耗竭。
总之,这些发现凸显了 CLICK 作为一种高效且通用的非病毒 CAR-NK 细胞改造平台,为下一代异体免疫细胞疗法提供了一种可规模化的方法。
Natural killer (NK) cells hold promise for adoptive cell therapy due to their innate cytotoxicity. Early clinical trials confirm their safety and efficacy in cancer and autoimmune disease treatment. Engineering NK cells with chimeric antigen receptors (CARs) enhances target specificity and facilitates their development as off-the-shelf allogeneic therapies.
However, both viral and non-viral engineering methods of NK cells present challenges.
Here, we introduce CISH locus integrated CAR killer (CLICK), a novel non-viral approach using a mini-circular single-stranded DNA genome editing system. CLICK enables efficient integration of CD19CAR sequences into the metabolic checkpoint CISH locus, simultaneously disrupting CISH and driving stable, progressively increasing CAR expression in peripheral blood-derived NK cells. CLICK-engineered CAR-NK cells exhibit potent cytotoxicity, enhanced anti-tumor activity ex vivo and in vivo , extended persistence, and reduced exhaustion.
Together, these findings highlight CLICK as a highly efficient and versatile platform for non-viral CAR-NK cell engineering, offering a scalable approach for next-generation allogeneic immune cell therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。